Literature DB >> 24785224

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

Robert J Motzer1, Thomas E Hutson, Lauren McCann, Keith Deen, Toni K Choueiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24785224     DOI： 10.1056/NEJMc1400731

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  98 in total

1.  Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.

Authors:  Yushi Zhang; Yongqiang Li; Yi Cai; Ke Wang; Hanzhong Li
Journal:  Cell Oncol (Dordr)       Date:  2015-11-23       Impact factor: 6.730

2.  [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].

Authors:  H Rexer
Journal:  Urologe A       Date:  2015-10       Impact factor: 0.639

Review 3.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

Review 4.  Principles of Kinase Inhibitor Therapy for Solid Tumors.

Authors:  Noah A Cohen; Teresa S Kim; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2017-02       Impact factor: 12.969

5.  Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.

Authors:  Carsten Nieder; Mohsan A Syed; Astrid Dalhaug; Adam Pawinski; Jan Norum
Journal:  Med Oncol       Date:  2017-07-26       Impact factor: 3.064

Review 6.  Pazopanib: a Review in Advanced Renal Cell Carcinoma.

Authors:  James E Frampton
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

7.  First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Authors:  Aly-Khan A Lalani; Haocheng Li; Daniel Y C Heng; Lori Wood; Austin Kalirai; Georg A Bjarnason; Hao-Wen Sim; Christian K Kollmannsberger; Anil Kapoor; Sebastien J Hotte; Marie Vanhuyse; Piotr Czaykowski; M Neil Reaume; Denis Soulieres; Peter Venner; Scott North; Naveen S Basappa
Journal:  Can Urol Assoc J       Date:  2017 Mar-Apr       Impact factor: 1.862

Review 8.  Pazopanib: a review of its use in the management of advanced renal cell carcinoma.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

9.  A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.

Authors:  Rana R McKay; Guillermo De Velasco; Lillian Werner; Joaquim Bellmunt; Lauren Harshman; Christopher Sweeney; Jonathan E Rosenberg; Michelle Hirsch; Sabina Signoretti; Eliezer M Van Allen; Meghara Walsh; Ulka Vaishampayan; David F McDermott; Toni K Choueiri
Journal:  Cancer       Date:  2016-05-19       Impact factor: 6.860

10.  Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Authors:  S Nazha; S Tanguay; A Kapoor; M Jewett; C Kollmannsberger; L Wood; G Bjarnason; D Heng; D Soulières; N Reaume; N Basappa; E Lévesque; A Dragomir
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.